UPDATED: Indications Table for BCMA and CD19 CAR-Ts US Approvals and Submissions
Here is a brief preview of this blast: New content: The Celltelligence team has created a BCMA CAR-T indications table for estimated US approvals and submissions following key Q2 2022 earnings presentations and recent press releases (see below for download). Of note, no updates were observed in Celltelligence’s CD19 CAR-T indications table.